Contract manufacturing organization

Recro to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

Friday, September 18, 2020 - 12:30pm

GAINESVILLE, Ga., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced that Gerri Henwood, the Companys President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Tuesday, September 22, 2020 at 4:10 p.m.

Key Points: 
  • GAINESVILLE, Ga., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced that Gerri Henwood, the Companys President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Tuesday, September 22, 2020 at 4:10 p.m.
  • A live webcast of the presentation will be available on the Presentations page within the Investors section of the Recro website at https://ir.recropharma.com .
  • A replay will be available on the Recro website for a period of 30 days following the event.
  • Recro is a contract development and manufacturing, or CDMO, business, with integrated solutions for the development, formulation, manufacturing and CTM management of high potency and other solid oral dose forms and located in Gainesville, GA.

The critical aspects to consider when choosing the right CDMO for your HPAPI Development, Manufacturing & Packaging, Upcoming Webinar Hosted by Xtalks

Thursday, September 17, 2020 - 1:30pm

In the webinar, the speakers will discuss accurate potent classification and the importance of OEL assessment.

Key Points: 
  • In the webinar, the speakers will discuss accurate potent classification and the importance of OEL assessment.
  • For more information or to register for this event, visit The critical aspects to consider when choosing the right CDMO for your HPAPI Development, Manufacturing & Packaging.
  • Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.)
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Samsung Biologics signs development agreement with Panolos for solid tumor treatment

Thursday, September 17, 2020 - 1:43am

INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors.

Key Points: 
  • INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors.
  • Under this agreement, Samsung Biologics will provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing.
  • "We are extremely proud to be partnering with Panolos in bringing PB101 closer to market," said Dr. Tae Han Kim, CEO Samsung Biologics.
  • Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services.

Seqens CDMO North America Appoints Jean-Noel David as Managing Director

Tuesday, September 15, 2020 - 2:45pm

Newburyport, MA & Ecully, FRANCE, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Seqens CDMO North America (formerly known as PCI Synthesis, Inc.), a pharmaceutical manufacturer of new chemical entities (NCEs), active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that it has appointed Jean-Noel David as Managing Director for North America.

Key Points: 
  • Newburyport, MA & Ecully, FRANCE, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Seqens CDMO North America (formerly known as PCI Synthesis, Inc.), a pharmaceutical manufacturer of new chemical entities (NCEs), active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that it has appointed Jean-Noel David as Managing Director for North America.
  • Davids mission is to grow Seqens CDMO business in North America, which includes plans to add manufacturing capacity, equipment and staff.
  • Seqens CDMO North America (formerly PCI Synthesis) is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, Mass., a division of Seqens CDMO, an integrated global leader in pharmaceutical synthesis and specialty ingredients with 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia.
  • To learn more about Seqens CDMO North America, its proprietary NCE development activities and process R&D capabilities please visit www.seqens.com .

Lubrizol Life Science Health Awarded Grant for Generic Contraceptive Injection Research to Advance Women’s Health Worldwide

Tuesday, September 15, 2020 - 2:00pm

The Lubrizol Corporation has announced that the contract development and manufacturing organization (CDMO) of Lubrizol Life Science Health (LLS Health) has been awarded a grant to support its research on injectable contraceptive formulations designed to bring accessible contraceptive products to women in developing nations.

Key Points: 
  • The Lubrizol Corporation has announced that the contract development and manufacturing organization (CDMO) of Lubrizol Life Science Health (LLS Health) has been awarded a grant to support its research on injectable contraceptive formulations designed to bring accessible contraceptive products to women in developing nations.
  • It is hoped that through funding from the Bill & Melinda Gates Foundation a contraceptive injection can be developed and manufactured in a format to allow for user self-administration to improve access.
  • LLS Health will manufacture batches of the injection formulation, placing them on a five-year stability program to assess the shelf life.
  • For more information on the CDMO Division of Lubrizol Life Science Health, visit www.lubrizolcdmo.com .

BriaCell to Present at the 3rd Annual Biologics World Nordic 2020

Tuesday, September 15, 2020 - 11:30am

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BriaCell or the Company) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that Dr. Bill Williams, BriaCells President & CEO, will be presenting at the 3rd Annual Biologics World Nordic 2020 Conference, a virtual event held during September 30 October 1, 2020.

Key Points: 
  • BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BriaCell or the Company) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that Dr. Bill Williams, BriaCells President & CEO, will be presenting at the 3rd Annual Biologics World Nordic 2020 Conference, a virtual event held during September 30 October 1, 2020.
  • The details of BriaCells presentation are as follows:
    Presentation Title: Targeted Immunotherapy for Breast Cancer: A Personalized Off-the-Shelf Approach
    In its third annual, Biologics World Nordic is the only focused biologic drugs and vaccines conference in the Nordic region.
  • It brings together the complete network of the Nordic biologics industry including the regions smaller biopharma, big pharma, international biopharma, contract manufacturing organizations (CMOs), clinical research organizations (CROs), technocrats and solution providers.
  • BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

2020 Analysis and Profile Directory of Contract Manufacturing Organizations in China's Biopharmaceutical Sector

Monday, September 14, 2020 - 2:45pm

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- The "Growth of Biopharmaceutical Contract Manufacturing Organizations in China: An In-depth Study of Emerging Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 14, 2020 /PRNewswire/ -- The "Growth of Biopharmaceutical Contract Manufacturing Organizations in China: An In-depth Study of Emerging Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This report on the China Contract Manufacturing Organizations (CMOs) industry covers regional industry developments, regulatory and legal changes, and reviews China's major CMO and CDMO companies with facility information, company ownership, background, management and facility capacity and history.
  • This study is based on in-depth research, using public secondary and primary information resources.
  • China mAb Therapeutics expected to grow to USD $26 billion by 2030, with CMOs accessing an increasing share of domestic production.

COVID-19 Recovery Analysis: Contract Development And Manufacturing Organization (CDMO) Outsourcing Market | Growing Pharmaceutical Industry to boost the Market Growth | Technavio

Friday, September 11, 2020 - 8:15am

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20200911005024/en/
    Technavio has announced its latest market research report titled Global Contract Development and Manufacturing Organization Outsourcing Market 2020-2024.
  • The growing pharmaceutical industry has been instrumental in driving the growth of the market.
  • Download a Free Sample Report on COVID-19 Impacts
    Contract Development and Manufacturing Organization (CDMO) Outsourcing Market 2020-2024: Segmentation
    Contract Development and Manufacturing Organization (CDMO) Outsourcing Market is segmented as below:

Avid Bioservices to Participate in 18th Annual Morgan Stanley Global Healthcare Conference

Thursday, September 10, 2020 - 1:05pm

TUSTIN, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc.(NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the 18th Annual Morgan Stanley Global Healthcare Conference.

Key Points: 
  • TUSTIN, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc.(NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the 18th Annual Morgan Stanley Global Healthcare Conference.
  • The conference, which will take place September 14-18, 2020, is being conducted with a virtual format.
  • Details of the companys participation are as follows:
    A webcast of the fireside chat will be made available.
  • Avid Bioservicesis a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture.

INOVIO Adds Thermo Fisher Scientific To Global Manufacturing Consortium

Tuesday, September 8, 2020 - 1:00pm

Thermo Fisher joins other contract development and manufacturing organizations in INOVIO's global manufacturing consortium, enabling INOVIO to potentially scale commercial production of INO-4800.

Key Points: 
  • Thermo Fisher joins other contract development and manufacturing organizations in INOVIO's global manufacturing consortium, enabling INOVIO to potentially scale commercial production of INO-4800.
  • "INOVIO welcomes Thermo Fisher to our global consortium of commercial scale vaccine manufacturers and we look forward to partnering with them on this critically important endeavor," said Dr. J. Joseph Kim, INOVIO's President & Chief Executive Officer.
  • Thermo Fisher Scientific will join existing partners Richter-Helm BioLogics and Ology Biosciences in INOVIO's global manufacturing consortium.
  • INOVIO is in active discussions with additional manufacturers to join the consortium as INOVIO seeks to complement its existing members with additional manufacturing partnerships to meet global supply needs.